Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
681-700 of 991 trials

Primary Sclerosing Cholangitis: Norucholic Acid Tablets

We are studying the safety and tolerability of norucholic acid tablets for people with primary sclerosing cholangitis. We also want to see if it effectively helps manage their condition.

Primary Sclerosing Cholangitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatology

FAPI PET Imaging for Pleural Mesothelioma

We are studying how effective FAPI PET scans are for diagnosing and staging pleural mesothelioma. This research may help improve treatment decisions and monitoring for patients with this condition.

Pleural Mesothelioma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngology

Acute Spinal Cord Injury: NG004 Treatment

We are testing a new antibody treatment for patients with acute spinal cord injuries to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Cervical Spinal Cord InjurySafety phase (I)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Ulcerative Pyoderma Gangrenosum: Spesolimab Study

We are testing whether spesolimab can help adults with ulcerative pyoderma gangrenosum heal their skin ulcers better than a placebo. This study aims to evaluate its safety and effectiveness.

Pyoderma GangrenosumConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementDermatology

Preventing Chemotherapy-Induced Nausea in Children: IV NEPA Study

We are studying a new intravenous treatment for children with cancer to see if it can effectively prevent nausea and vomiting during chemotherapy. This trial compares IV NEPA with standard treatments to ensure safety and effectiveness.

Chemotherapy-Induced Nausea and Vomiting3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncologyPediatrics

Ocular Melanoma: Roginolisib Treatment Study

We are studying the effectiveness of roginolisib for patients with advanced ocular or uveal melanoma compared to standard therapies. The trial will also assess safety and quality of life impacts.

Uveal MelanomaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

Idiopathic Retroperitoneal Fibrosis: Early Steroid Discontinuation Study

We are investigating whether stopping steroid treatment early in patients with idiopathic retroperitoneal fibrosis affects relapse rates. This study aims to improve treatment strategies for managing this condition.

Idiopathic Retroperitoneal Fibrosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Systemic Lupus Erythematosus: Cenerimod Study

We are examining the long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus. This study looks at how the medication works alongside existing treatments.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Chronic Immune Thrombocytopenia: Mezagitamab Injection

We are studying a new injection, mezagitamab, for adults with chronic immune thrombocytopenia to see if it can improve platelet counts and reduce symptoms compared to a placebo.

Primary Immune Thrombocytopenia6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematology

Ileal Crohn’s Disease: AZD7798 Study

We are testing the safety and effectiveness of AZD7798 in adults with ileal Crohn’s disease who have an ileostomy. This study aims to see how well the treatment helps with healing and managing symptoms.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

BCG Vaccination: Understanding Immune Response

We are studying how pre-vaccination immune status affects the response to the BCG vaccine. This research may help improve vaccination strategies by identifying key immune factors.

Healthy Participants>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

AMG 193 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, AMG 193, for patients with advanced non-small cell lung cancer that has a specific genetic deletion. The trial aims to evaluate its safety and effectiveness compared to existing options.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Lung Cancer: ABBV-400 and Budigalimab Study

We are testing a new treatment combining ABBV-400 and Budigalimab for adults with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to see how safe it is and how well it works.

Advanced Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Giant Cell Arteritis and Rheumatoid Arthritis: PET/CT Imaging Study

We are testing a new imaging method to see inflamed arteries in giant cell arteritis and inflamed joints in rheumatoid arthritis. This study aims to improve how we visualize and understand these conditions.

Giant Cell ArteritisRheumatoid Arthritis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyRheumatology

Giant Cell Arteritis: Imaging Study with [18F]fluor-PEG-folate

We are investigating how well a special imaging technique shows changes in arteries of patients with giant cell arteritis before and after treatment. This may help us understand the disease better and improve future care.

Giant Cell Arteritis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementRheumatology

Severe Autoimmune Encephalitis: Bortezomib Study

We are investigating whether bortezomib is effective and safe for patients with severe autoimmune encephalitis. This trial focuses on individuals with specific autoantibodies related to their condition.

Autoimmune Encephalitis3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementNeurologyRheumatology

Focal Onset Seizures: Extended-Release Levetiracetam Study

We are testing a new once-daily version of levetiracetam for people with drug-resistant focal onset seizures. The study aims to see if it reduces seizure frequency better than current treatments and a placebo.

Refractory Epilepsy3-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Systemic Sclerosis: Efgartigimod PH20 SC Study

We are testing a new treatment for adults with systemic sclerosis to see if it improves skin symptoms and overall health compared to a placebo. The study will also look at safety and how well the treatment works.

Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Hidradenitis Suppurativa: AVTX-009 Treatment Study

We are evaluating a new treatment, AVTX-009, for individuals with moderate to severe hidradenitis suppurativa. The goal is to see if it works better than a placebo and to check its safety.

Hidradenitis Suppurativa3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

Small Cell Lung Cancer: 68Ga-EVG321 Diagnostic Study

We are studying a new diagnostic agent to see how it spreads in the body of patients with small cell lung cancer. The trial also looks at its safety and how the body processes it.

Small Cell Lung Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology